ScholarIQanswers from OpenAlex

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer

PaperCitations, authors & open-access status

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer have?

ScholarIQcitation count

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer has 424 citations in the OpenAlex counts ScholarIQ stores.

When was Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer published?

ScholarIQyear

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer has 2019 year in the ScholarIQ index.

Open the OpenAlex record →

What is the open-access status of Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer?

ScholarIQoa status

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer has closed oa status in the ScholarIQ index.

Open the OpenAlex record →

What is the DOI of Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer?

ScholarIQdoi

The DOI for Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer is on the source record.

Open the DOI →

What is the PMID of Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer?

ScholarIQpmid

The PMID for Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer is on the source record.

Open the PMID →

What is the OpenAlex record for Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer?

ScholarIQopenalex

The OpenAlex for Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer is on the source record.

Open the OpenAlex →

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer

How many citations does Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer have?

When was Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer published?

What is the open-access status of Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer?

What is the DOI of Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer?

What is the PMID of Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer?

What is the OpenAlex record for Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer?

Related on ScholarIQ